Archive for August, 2011

KERX Perifosine to continue to completion as expected

Aug 31, 2011 No Comments by

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) and Aeterna Zentaris Inc. (NASDAQ: AEZS) announced today that the independent Data Safety Monitoring Board (DSMB) for its pivotal Phase 3 X-PECT study of KRX-0401 (perifosine) in patients with refractory advanced colorectal cancer has completed a pre-specified interim analysis for safety and futility. The independent DSMB has recommended that the […]

Daily News Read more

PATH CRL. PGNX PDUFA date + BNVI AEZS ANX updates

Aug 30, 2011 No Comments by

Bionovo, Inc. (NASDAQ: BNVI) said today that it is now in a position to initiate its Phase 3 trial of Menerba this fall for hot flashes. Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) today announced favorable top-line results of its completed Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth […]

Daily News Read more

TLON receives Marqibo SPA. BNVI Menerba update tmrw + QLTI

Aug 29, 2011 No Comments by

Bionovo, Inc. (NASDAQ: BNVI) announced today that it will host a conference call on Tuesday, August 30, 2011, to discuss the results of the completed Tolerability Trial of its drug candidate for menopausal hot flashes, Menerba, at 2:00 p.m. Pacific Time. It will also discuss its overall clinical development plan and the impending Phase 3 […]

Daily News Read more

IMMU pipeline update. PPHM Ph2 breast cancer data. ZGNX to raise cash

Aug 24, 2011 No Comments

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced 20.7 month median overall survival (OS) from a prior single-arm Phase 2 trial evaluating bavituximab in combination with docetaxel in patients with locally advanced or metastatic breast cancer. Immunomedics, Inc. (Nasdaq:IMMU) gave a pipeline update today saying that it intends to initiate a Phase 3 trial in 2012 […]

Read more

IMMU pipeline update. PPHM Ph2 breast cancer data. ZGNX to raise cash

Aug 24, 2011 No Comments

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced 20.7 month median overall survival (OS) from a prior single-arm Phase 2 trial evaluating bavituximab in combination with docetaxel in patients with locally advanced or metastatic breast cancer. Immunomedics, Inc. (Nasdaq:IMMU) gave a pipeline update today saying that it intends to initiate a Phase 3 trial in 2012 […]

Read more

VVUS raises cash. SGEN initiates Phase 2 NHL. CTIC MAA update

Aug 23, 2011 No Comments

 VIVUS, Inc. (NASDAQ: VVUS), today announced that it has entered into definitive agreements sell 6,889,098 shares of its common stock in a registered direct offering at $6.65 per share, resulting in gross proceeds of approximately $45.8 million. Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that it has initiated a phase 2 clinical trial of ADCETRIS(TM) (brentuximab […]

Read more

ARIA files MAA. PLX refiles NDA. AMRN on target for September NDA filing

Aug 08, 2011 No Comments

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its ridaforolimus partner, Merck, has submitted a marketing authorization application (MAA) for ridaforolimus with the European Medicines Agency (EMA). The submission occurred on July 29, 2011. Amarin Corporation plc (Nasdaq:AMRN) announced today the successful completion of all remaining studies required for its NDA for AMR101 for the […]

Read more

MAPP PDUFA date. INSM Phase 3 on hold + IGXT RIGL ARIA

Aug 02, 2011 No Comments

Insmed Incorporated (Nasdaq: INSM), announced the FDA has placed a clinical hold on its Phase 3 clinical trials for ARIKACE in Cystic Fibrosis (CF) patients with Pseudomonas lung infections and patients with non-tuberculous mycobacterial (NTM) lung disease. It has been informed by the FDA that this decision was based on an initial review of the […]

Read more

7 companies facing upcoming reverse splits or NASDAQ delist

Aug 01, 2011 No Comments

If companies are unable to push their bid price above $1 they either face delisting from NASDAQ to OTCBB or will require a reverse split to remain on NASDAQ. Most of the companies below face no meaningful upcoming catalysts to propel their bid price above $1. Which companies are in this category? I have 7 […]

Read more